These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26482620)

  • 1. Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.
    Ali Y; Abd Hamid S
    Tumour Biol; 2016 Jan; 37(1):47-55. PubMed ID: 26482620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
    Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
    Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
    Rossman J; Reddy V; Cantor A; Miley D; Robert F
    Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Topoisomerase IIa expression in correlation with clinical and morphological parameters and proliferation (based on argyrophilic proteins of nucleolar organizer regions and Ki-67 antigen) in lung adenocarcinoma].
    Kodiakov DS; Klimachëv VV; Avdalian AM; Bobrov IP; Lazarev AF; Lushnikova EL; Nepomiashchikh LM
    Vopr Onkol; 2014; 60(2):63-8. PubMed ID: 24919264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
    Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
    Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha.
    Hua W; Sa KD; Zhang X; Jia LT; Zhao J; Yang AG; Zhang R; Fan J; Bian K
    Biochem Biophys Res Commun; 2015 Aug; 463(4):1077-83. PubMed ID: 26079880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays.
    Tsiambas E; Karameris A; Tiniakos DG; Karakitsos P
    Pancreatology; 2007; 7(1):45-52. PubMed ID: 17449965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
    Hughes C; Murphy A; Martin C; Fox E; Ring M; Sheils O; Loftus B; O'Leary J
    J Clin Pathol; 2006 Jul; 59(7):721-4. PubMed ID: 16556661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Thapa U; Thapa P; Karki R; Yun M; Choi JH; Jahng Y; Lee E; Jeon KH; Na Y; Ha EM; Cho WJ; Kwon Y; Lee ES
    Eur J Med Chem; 2011 Aug; 46(8):3201-9. PubMed ID: 21601964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma.
    Ben Abdelkrim S; Rammeh S; Ziadi S; Tlili T; Jaidane M; Mokni M
    J Immunoassay Immunochem; 2014; 35(4):358-67. PubMed ID: 24624938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.
    Jacot W; Fiche M; Zaman K; Wolfer A; Lamy PJ
    Biochim Biophys Acta; 2013 Aug; 1836(1):146-57. PubMed ID: 23628726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
    Mrklić I; Spagnoli GC; Juretić A; Pogorelić Z; Tomić S
    Acta Histochem; 2014 Jun; 116(5):740-6. PubMed ID: 24560456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase II alpha expression in breast ductal invasive carcinomas and correlation with clinicopathological variables.
    Kalogeraki A; Ieromonachou P; Kafousi M; Giannikaki E; Vrekoussis T; Zoras O; Tsiftsis D; Delides G; Stathopoulos E
    In Vivo; 2005; 19(5):837-40. PubMed ID: 16097435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
    Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
    Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
    Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.